A deuterated morpholiniazole and its use

By replacing the 2-position methyl hydrogen of 2-methyl-5-nitroimidazole with deuterium, the half-life of the drug is extended, and the existing morpholinidazole drug is solved, and the problem of large doses and short action time is achieved. Good pharmacodynamic and pharmacokinetic properties are particularly effective against anaerobic bacterial infection and amoeba infection.

CN114907250BActive Publication Date: 2024-11-22HC SYNTHETIC PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110164957.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-02-06
Publication Date
2024-11-22
Estimated Expiration
2041-02-06

AI Technical Summary

Technical Problem

The existing morpholinidazole drugs are large in dosage and short in action, making it difficult to meet long-term treatment needs.

Method used

By replacing 2-position methyl hydrogen of 2-methyl-5-nitroimidazole with deuterium, 2-trideuterated methyl-5-nitroimidazole derivatives are prepared to prolong the half-life of the drug and thus reduce the number of medications. and quantity. The compound is synthesized by glyoxaldehyde, deuterated acetaldehyde, ammonia water reaction, nitration, epoxidation and morpholine reactions.

Benefits of technology

It significantly prolongs the half-life of the drug, improves pharmacodynamic and pharmacokinetic properties, reduces the dosage and number of drugs, and has good effects on anaerobic bacterial infection and amoeba infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure DEST_PATH_IMAGE002
    Figure DEST_PATH_IMAGE002
  • Figure DEST_PATH_IMAGE004
    Figure DEST_PATH_IMAGE004
  • Figure DEST_PATH_IMAGE006
    Figure DEST_PATH_IMAGE006
Patent Text Reader

Abstract

The present invention provides deuterated morpholino nidazole, its pharmaceutically acceptable salt, stereoisomer, hydrate, solvate, preparation method, pharmaceutical composition, preparation and use thereof. The compound or its salt, pharmaceutical composition and preparation have good antagonistic effect on anaerobic bacteria and amoeba, and have better effect than morpholino nidazole.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of chemical medicines, and particularly relates to a deuterated morpholino nidazole and a preparation method thereof. The present invention also relates to the use of a deuterated morpholino nidazole pharmaceutical composition in treating anaerobic bacteria infection, protozoan infection and various other diseases. Background Art

[0002] Morpholino is an antibacterial and antiparasitic drug that has been clinically proven to have good effects. It is the third generation of 2-methyl-5-nitroimidazole derivatives and is one of the leading nitroimidazole products on the market.

[0003] In the long-term medication practice, it is found that the dosage of this type of drug is large and the duration of action of a single dose is short. In order to further prolong the duration of drug action and reduce the dosage, through theoretical analysis and experimental exploration, it is found that 2-trideuterated methyl-5-nitroimidazole derivatives can meet this requirement. After the 2-methyl hydrogen at the 2-position of 2-methyl-5-nitroimidazole is deuterated, the half-life of this type of drug can be prolonged, thereby achieving the purpose of reducing the number of medications and the dosage. Summary of the invention

[0004] In view of the above technical problems, the present invention discloses a 2-methyl-5-nitroimidazole compound and a composition comprising the compound, which has better pharmacodynamics or pharmacokinetic properties as an antibacterial and antiparasitic drug.

[0005] To this end, the present invention adopts the following technical solutions:

[0006] In one aspect, the present invention provides a 2-methyl-5-nitroimidazole compound of formula I, or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0007]

[0008] Formula I

[0009] In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently hydrogen or deuterium, and further, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8At least one of them is deuterium.

[0010] Preferably, when R 1 , R 2 , R 3 When all are deuterium, the compound is as shown in Formula II:

[0011]

[0012] Formula II

[0013] To further illustrate, the compound of formula II includes its racemate, levorotatory isomer, dextrorotatory isomer, hydrate, solvate and pharmaceutically acceptable salt.

[0014] The second aspect of the present invention provides a method for preparing the compound of the first aspect of the present invention. The reaction principles and technical means used in the synthesis process are described in general organic chemistry textbooks, but the method for introducing the deuterated structure of the present invention has not been reported.

[0015] The present invention prepares 2-deuterated methylimidazole by reacting glyoxal, deuterated acetaldehyde and ammonia water, further nitrifies to obtain 2-deuterated methyl-5-nitroimidazole, and then reacts with epichlorohydrin to obtain deuterated ornidazole, and further reacts with sodium hydroxide solution to obtain an epoxide compound, and then reacts with morpholine to obtain a compound of formula II. The reaction equation is as follows:

[0016]

[0017] The third aspect of the present invention provides a method for preparing a pharmaceutical composition, comprising the steps of: mixing a pharmaceutically acceptable carrier with the compound of the first aspect of the present invention or a pharmaceutically acceptable salt, stereoisomer, hydrate, solvate, etc. thereof to form a pharmaceutical composition.

[0018] The fourth aspect of the present invention provides a pharmaceutical composition, which is a mixture of the compound of the first aspect of the present invention or its pharmaceutically acceptable salt, stereoisomer, hydrate, solvate, etc. and a pharmaceutically acceptable carrier.

[0019] The compounds of the present invention can be administered orally or parenterally, such as intravenously, subcutaneously, intraperitoneally, topically, etc. The dosage can vary depending on the specific compound, the mode of administration, the symptoms and severity of the disease to be treated, and the physical condition of the individual receiving the drug.

[0020] The compound of the present invention shows strong antibacterial and antiparasitic effects, and has particularly good effects on anaerobic bacteria infection and amoeba infection. Specific embodiment:

[0022] In order to describe the content of the present invention in more detail, some specific preparation methods are listed below, but these specific preparation methods do not constitute any limitation to the present invention. The compounds of the present invention can also be conveniently prepared by combining various methods known in the art, and such combinations can be easily implemented by those skilled in the art.

[0023] Example 1: Preparation of 2-trideuterated methylimidazole

[0024] Mix 51 ml of 25% ammonia water and 90 ml of water, cool to 5-10°C, slowly drop 40 ml of 40% trideuteroacetaldehyde and 38.5 ml of 40% glyoxal, react at 40°C for 2 hours, then heat to 80°C for 2 hours, cool to room temperature, filter, concentrate the filtrate at below 60°C to 1 / 3 of the original volume under reduced pressure, cool to crystallize, filter, and dry to obtain 19.3 g of 2-deuteromethylimidazole.

[0025] Example 2: Preparation of 2-trideuterated methyl-5-nitroimidazole

[0026] 30g of 2-deuterated methylimidazole was added into the reaction bottle, and 75g of sulfuric acid was added under stirring. The reaction temperature was controlled below 130°C. After 2-deuterated methylimidazole was dissolved, the temperature was raised to 140°C, and 70g of nitric acid was added. After the addition was complete, the reaction was kept warm for 3 hours, and then neutralized with ammonia water, filtered, and dried to obtain 32g of the product.

[0027] Example 3: Preparation of trideuterated ornidazole

[0028] Take 10g of 2-trideuterated methyl-5-nitroimidazole, add 200ml of ethyl acetate to dissolve, then add 10g of anhydrous aluminum chloride, stir and cool to 0°C, add 20g of epichlorohydrin dropwise, keep warm for reaction, after the reaction is completed, slowly add the reaction solution into water for hydrolysis, separate the ethyl acetate layer, extract the ethyl acetate layer with 10% hydrochloric acid solution, finally adjust the pH of the acid water layer to 7 with ammonia water, filter and dry solid precipitated to obtain 4.8g of trideuterated ornidazole.

[0029] Example 4: Preparation of trideuterated morpholinonitrile:

[0030] Reflux trideuterated ornidazole (10 g), morpholine (9 g) and 100 ml of acetonitrile for 5 hours, recover the acetonitrile under reduced pressure, add 100 ml of water, heat until completely dissolved, add saturated sodium bicarbonate solution to adjust the pH to 8, filter hot, cool to crystallize, filter and dry to obtain 10 g of white solid.

[0031] Example 5: Preparation of L-trideuterated ornidazole:

[0032] To a mixture of 35 ml formic acid and 1 ml concentrated sulfuric acid, add 2-trideuterated methyl-5-nitroimidazole (6.6 g) under stirring, cool to 0-5°C, add S-(+)-epichlorohydrin (23.0 g) dropwise, and react at room temperature for 10 hours after the addition is complete. Recover the solvent under reduced pressure, then add ice water (10 ml) to the residue, then wash with toluene (25 ml x 5), adjust the pH of the aqueous layer to 7-8 with concentrated ammonia water, precipitate solid, filter, and dry to obtain 5.9 g of left-handed trideuterated ornidazole.

[0033] Example 6: Preparation of dextrorotatory trideuterated ornidazole:

[0034] To a mixture of 35 ml formic acid and 1 ml concentrated sulfuric acid, add 2-trideuterated methyl-5-nitroimidazole (6.6 g) under stirring, cool to 0-5°C, add R-(-)-epichlorohydrin (23.0 g) dropwise, and react at room temperature for 10 hours after the addition is complete. Recover the solvent under reduced pressure, then add ice water (10 ml) to the residue, then wash with toluene (25 ml x 5), adjust the pH of the aqueous layer to 7-8 with concentrated ammonia water, precipitate solid, filter, and dry to obtain 5.9 g of right-rotating trideuterated ornidazole.

[0035] Example 7: Preparation of trideuterated ornidazole epoxide:

[0036] Trideuterated ornidazole (10 g) was added to 100 ml of methanol, and 3 ml of 10% sodium hydroxide was added. The mixture was heated under reflux for 2 hours and filtered to obtain 8.2 g of ornidazole epoxide.

[0037] Example 8: Preparation of L-trideuterated morpholinonitrile:

[0038] Reflux L-trideuterated ornidazole epoxide (10 g), morpholine (9 g), and 100 ml of acetonitrile for 5 hours, recover the acetonitrile under reduced pressure, add 100 ml of water, heat until completely dissolved, add saturated sodium bicarbonate solution to adjust the pH to 8, filter hot, cool and crystallize, filter and dry to obtain 10 g of L-trideuterated morpholinonitrile as a white solid.

[0039] Example 9: Preparation of dextrorotatory trideuterated morpholinonitrile:

[0040] Reflux right-rotating trideuterated ornidazole epoxide (10 g), morpholine (9 g), and 100 ml of acetonitrile for 5 hours, recover the acetonitrile under reduced pressure, add 100 ml of water, heat until completely dissolved, add saturated sodium bicarbonate solution to adjust the pH to 8, filter hot, cool and crystallize, filter and dry to obtain 10 g of right-rotating trideuterated morpholinonitrile as a white solid.

[0041] Example 10: Preparation of L-trideuterated morpholinonitrile tablets

[0042] prescription:

[0043] L-Trideuterated morpholinonitrile 150g

[0044] 70g starch

[0045] Microcrystalline cellulose 125g

[0046] Magnesium stearate 2.0g

[0047] Hydroxypropyl methylcellulose (4% solution)

[0048] 1000 pieces

[0049] Preparation method: Prepare 4% hydroxypropyl methylcellulose solution for later use. Weigh 10g starch and dry it at 105℃ for 5h for later use. Take 40g starch and the prescribed amount of trideuterated ornidazole and microcrystalline cellulose, mix well, and crush through an 80-mesh sieve. Use 4% hydroxypropyl methylcellulose solution to make a soft material, granulate with a 20-mesh sieve, dry at 50-60℃ until the moisture content of the granules is about 3%, pass through a 20-mesh sieve to granulate, add the prescribed amount of dry starch and magnesium stearate, finally mix, measure the intermediate content, determine the tablet weight, and press the tablet.

[0050] Example 11: Preparation of L-trideuterated morpholinonitrile sodium chloride infusion

[0051] prescription:

[0052] L-Trideuterated morpholinonitrile 50g

[0053] Sodium chloride 85g

[0054] Water for injection 10L

[0055] Make 100 bottles

[0056] Preparation method: Weigh the prescribed amount of trideuterated morpholinonitrile and sodium chloride, add 10L of water for injection, stir, then add 0.1% activated carbon, stir for 15 minutes, decarbonize with a 5-micron titanium rod, and then filter through a 0.45-micron and 0.22-micron microporous filter membrane of a cartridge filter, fill into a 100ml glass bottle, and steam sterilize at 115℃ for 30 minutes to obtain trideuterated morpholinonitrile sodium chloride injection.

[0057] Test Example 1:

[0058] The compounds of the present invention were tested for anti-anaerobic bacteria using methods known to those skilled in the art. The results showed that the compounds of the present invention had good in vitro antibacterial activity against two anaerobic bacteria, and their effects were stronger than those of morpholinothiazolin. The specific results are shown in Table 1:

[0059] Table 1 In vitro antibacterial activity against two anaerobic bacteria

[0060]

[0061] Test Example 2:

[0062] Preliminary toxicity test, acute toxicity test on mice with morpholino as control drug, LD50 was determined by tail vein injection of mice. The results of acute toxicity study of the compound of the present invention and morpholino are shown in Table 2 below:

[0063] Table 2 Acute toxicity test on mice

[0064] Compound LD50 LD50 average confidence limit Morpholinazole 618mg / kg 618±6.18 mg / kg Trideuterated morpholinonitrile 853mg / kg 853±8.53 mg / kg Levomorpholinidazole 880mg / kg 880±8.80 mg / kg L-Trideuterated morpholinonitrile 925mg / kg 925±9.25 mg / kg

[0065] Tests show that the compounds of the present invention are less toxic than morpholinium nitrazole.

[0066] Experimental Example 3: The compound of the present invention and morpholinazole were prepared into 5 mg / ml solutions, and 0.5 ml was administered to mice by intravenous injection. Blood samples were taken every 0.5 hours after each single-variety injection, and the changes in drug concentration in the mice were detected by HPLC to determine the metabolic rate of the drug in the mice. The specific test results are shown in Table 3 below:

[0067] Table 3 Metabolic rates of morpholinoazole and the inventive compounds in mice

[0068] Compound <![CDATA[Half-life (t 1 / 2 ).]]> Morpholinazole 2.5h Trideuterated morpholinonitrile 3h Levomorpholinidazole 2.5h L-Trideuterated morpholinonitrile 3.5h

[0069] The test results show that the compound of the present invention has a slower metabolism rate in vivo than morpholinoazole.

Claims

1. A compound of formula II The compound represented by the structure of formula II includes the corresponding racemic isomer and levorotatory isomer.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound according to claim 1 and a pharmaceutically acceptable salt thereof.

3. Use of the compound according to claim 1 and its pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 2 in the preparation of drugs for treating anaerobic bacterial infection or protozoan infection.